Vaxart (VXRT) Expected to Post Quarterly Earnings on Thursday

Vaxart (OTCMKTS:VXRT) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $26.2120 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 4:30 PM ET.

Vaxart (OTCMKTS:VXRT) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. The company had revenue of $39.23 million during the quarter, compared to analyst estimates of $50.50 million. Vaxart had a net margin of 14.51% and a return on equity of 61.43%. On average, analysts expect Vaxart to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vaxart Stock Up 1.7%

Shares of Vaxart stock traded up $0.01 during trading on Tuesday, hitting $0.60. The stock had a trading volume of 270,976 shares, compared to its average volume of 560,625. The stock has a 50 day simple moving average of $0.56 and a 200 day simple moving average of $0.63. The company has a market capitalization of $145.70 million, a PE ratio of 4.00 and a beta of 1.10. Vaxart has a 1 year low of $0.30 and a 1 year high of $0.84.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Vaxart to a “hold” rating in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Vaxart

Several institutional investors and hedge funds have recently bought and sold shares of VXRT. Marshall Wace LLP bought a new stake in Vaxart in the second quarter worth approximately $794,000. Jones Financial Companies Lllp raised its holdings in shares of Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 478,111 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in shares of Vaxart during the 1st quarter valued at $31,000. Creative Planning acquired a new stake in shares of Vaxart in the 2nd quarter valued at $33,000. Finally, Invesco Ltd. lifted its stake in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares during the last quarter. Hedge funds and other institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.